
Opinion|Videos|January 16, 2026
The Impact of Clinical and Genomic Factors on Real-World Outcomes With Elacestrant in ESR1+ Breast Cancer
Author(s)Hope S. Rugo, MD, FASCO, Seth Wander, MD, PhD
Explore the impact of elacestrant on ESR1-mutated breast cancer, revealing real-world data insights and genomic factors influencing treatment outcomes.
Advertisement
Episodes in this series

Hope S. Rugo, MD, and Seth Wander, MD, PhD, examine how clinical characteristics and genomic alterations influence real-world outcomes with elacestrant in ESR1-mutant breast cancer. They discuss correlations between mutation profiles, treatment response, and durability of benefit. Rugo and Wander highlight how these insights may refine patient selection in routine practice.
Advertisement
Related to this article

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.

Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship Training
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.

Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.

Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.

The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.

The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
3
Beyond the Target: Payloads, Therapeutic Windows, and Biomarkers Shape the Next Wave of ADCs in NSCLC
4
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
5

